Search results
Showing 496 to 501 of 501 results for cost benefit of cancer drugs
More than 1,000 people each year will benefit from NICE's recommendation.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).